西班牙新药可及背景下免疫性血小板减少症治疗的临床实践:基于德尔菲法的西班牙专家小组共识
免疫性血小板减少症(ITP)是一种常见的自身免疫性血液病,诊断因临床异质性和缺乏特异性检测而具有挑战性。西班牙ITP专家小组采用德尔菲法,由科学委员会设计涵盖13个主题、共127项条目的问卷,覆盖成人ITP管理的尽可能多的场景。最终达成共识的条目为103项,共识率81%。该共识基于真实临床实践数据,就ITP诊断、治疗和管理提供实践推荐,但部分方面专家间仍未达成共识,需更多进展优化ITP管理。
要点
- 西班牙ITP专家小组采用德尔菲法,问卷涵盖13个主题、共127项条目,最终103项达成共识(81%)。
- 共识覆盖成人ITP诊断、一线治疗、二线治疗、难治性患者治疗、随访、急诊与手术、老年ITP、妊娠ITP、抗凝与抗血小板、继发性ITP、生活质量、TPO-RA停药及ITP与新冠等13个章节。
- 该共识基于真实临床实践数据,就ITP诊断、治疗和管理提供实践推荐,以帮助医生改善患者结局。
- 部分方面专家间仍未达成共识,原文指出需更多进展以优化ITP管理。
适用人群与场景
- 成人免疫性血小板减少症(ITP)患者,管理场景涵盖诊断、一线治疗、二线治疗、难治性患者治疗、随访、急诊与手术、老年、妊娠、抗凝与抗血小板、继发性ITP、生活质量、TPO-RA停药及新冠等13个章节所覆盖的场景。
诊断标准与关键阈值
- ITP定义为自身抗体介导的加速破坏和生成不足所致的血液自身免疫性疾病,血小板计数<100 × 10^9/L。
研究设计与关键结果
- 西班牙ITP专家小组开展德尔菲共识研究,科学委员会定义127项共识条目,对应13个章节,最终达成共识的条目为103项,德尔菲问卷最终共识百分比为81%。
证据类型、等级与局限
- 证据类型:德尔菲专家共识;共识率81%(103/127项条目达成共识)。
- 局限:部分方面仍未明确、专家间未达成共识,原文指出需更多进展以优化ITP管理。
对床旁实践的改变
- 该共识基于真实临床实践数据,就ITP诊断、治疗和管理提供实践推荐,以帮助临床医生应对该疾病并为患者实现最佳结局。
指南或共识出处
- 西班牙ITP专家小组德尔菲共识(Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Immune thrombocytopenia (ITP) is a common autoimmune hematological disorder. Despite this, diagnosis is still challenging due to clinical heterogeneity and the lack of a specific diagnostic test. New findings in the pathology and the availability of new drugs have led to the development of different guidelines worldwide. In the present study, the Delphi methodology has been used to get a consensus on the management of adult patients with ITP in Spain and to help in decision-making. The Delphi questionnaire has been designed by a scientific ad hoc committee and has been divided into 13 topics, with a total of 127 items, covering the maximum possible scenarios for the management of ITP. As a result of the study, a total consensus of 81% has been reached. It is concluded that this Delphi consensus provides practical recommendations on topics related to diagnosis and management of ITP patients to help doctors to improve outcomes. Some aspects remain unclear, without consensus among the experts. Thus, more advances are needed to optimize ITP management.
What is the context? Immune thrombocytopenia (ITP) is a hematologic autoimmune disease characterized by accelerated destruction and inadequate production of platelets mediated by autoantibodies (platelet count <100 × 109 /L).Despite being a common condition, its heterogeneous clinical course makes its diagnosis and management still a challenge.In recent years, new molecules with different mechanisms of action have emerged for the treatment of ITP.Due to the increasing information about the pathology and its therapies, several international guidelines have recently been established to provide recommendations for the management and treatment of ITP.There are still many patient scenarios and disease aspects which are not addressed in the guidelines.What is new? Our Spanish ITP Expert Group has developed a Delphi consensus study to provide recommendations and promote standardization of the management of adult patients with ITP in Spain.The scientific committee defined 127 statements for consensus, corresponding to 13 chapters: (i) Diagnosis of ITP, (ii) First-line treatment, (iii) Second-line treatment, (iv) Treatment of refractory patients, (v) Follow-up, (vi) Emergency and surgery, (vii) ITP in the elderly, (viii) ITP in pregnancy, (ix) Anticoagulation and antiplatelet, (x) Secondary ITP, (xi) Quality of life, (xii) Discontinuation of TPO-RA, and (xiii) ITP and Covid.The total number of agreed statements achieved was 103, giving a final percentage of consensus in the Delphi questionnaire of 81%.What is the impact? This Delphi consensus provides recommendations based on real clinical practice data, regarding the diagnosis, treatment, and management of patients and scenarios in ITP to assist clinicians in addressing this disease and achieving optimal outcomes for the patient.
参考来源
- González-López TJ, Bárez A, Bernardo-Gutiérrez Á, et al. Real-life clinical practice in Spain in the setting of new drug availability for ITP treatment. A Delphi-based Spanish expert panel consensus. Platelets. 2024. PMID: 38742687. doi:10.1080/09537104.2024.2336104
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。